Search

Your search keyword '"Ong, Aldrich"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Ong, Aldrich" Remove constraint Author: "Ong, Aldrich"
47 results on '"Ong, Aldrich"'

Search Results

1. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

2. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

3. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial

4. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

5. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

8. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

9. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials

11. Factors Associated with Long-Term Prostate Cancer Survival after Palliative Radiotherapy to a Bone Metastasis and Contemporary Palliative Systemic Therapy: A Retrospective, Population-Based Study

13. Every-other-day or once-a-week: Long-term efficacy outcomes of the multicenter randomised PATRIOT prostate SBRT trial.

14. Abstract 4858: Effect of mTOR activity in peripheral blood mononuclear cells with metformin in high-risk prostate cancer patients receiving external beam radiotherapy and androgen deprivation therapy

15. 168: Identification of Factors Associated with Prolonged Survival in Prostate Cancer Patients Post-Receipt of Palliative Radiotherapy to a Bone Metastasis: A Retrospective, Population-Based Study

18. Do Sustainable Palliative Single Fraction Radiotherapy Practices Proliferate or Perish 2 Years after a Knowledge Translation Campaign?

21. Do sustainable palliative single fraction radiotherapy practices proliferate or perish 2 years after a knowledge translation campaign?

22. 123: Do Sustainable Palliative Single Fraction Radiotherapy Practices Proliferate or Perish Two Years After a Knowledge Translation Campaign?

25. Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled Trial

27. 1: Interim Analysis of a Phase II Multi-Institution Randomized, Placebo-Controlled Trial, The Premium Trial (Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate)

29. 41: Do Coordinated Knowledge Translation Campaigns Persuade Radiation Oncologists to Utilize Single Fraction Radiotherapy Over Multiple Fraction Radiotherapy for Bone Metastases?

30. 2: Acute and Subacute Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo Plus Prostate and Pelvic Radiotherapy for the Management of High Risk Prostate Cancer: Interim Toxicity Results of a Double-Blinded, Multicentre, Phase Ii Randomized Controlled Trial

31. 30: Is Intermittent Androgen Deprivation Therapy An Underutilized Strategy for Management of Relapsed, Non-Metastatic, Castration Sensitive Prostate Cancer? - A Population-Based Assessment of a Provincial Cancer Program

32. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)

33. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy

34. 100 Real World Utilization of Intermittent Androgen Deprivation Therapy (IADT) for Castration Sensitive Metastatic Prostate Cancer in Manitoba

35. 220 Impact of Dissemination of Choosing Wisely Canada (CWC) Recommendations on Utilization of Palliative Single Fraction (SFRT) for Bone Metastases in Manitoba

37. Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.

40. PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.

41. E-cadherin promotes tumorigenicity in human ovarian surface epithelium

43. Identification of the TIMP-2 Binding Site on the Gelatinase A Hemopexin C-Domain by Site-Directed Mutagenesis and the Yeast Two-Hybrid System

47. 454: SABR for favourable-risk prostate cancer: 10-year outcomes and second malignancies.

Catalog

Books, media, physical & digital resources